Current Treatment Options for Metastatic Urothelial Cancer
Jonathan E. Rosenberg, MD, discusses what the frontline treatment landscape for metastatic urothelial cancer currently looks like.
Watch
Testing for NTRK Gene Fusions in the Community Setting
Alexander Drilon, MD, discusses what community oncologists should know about testing for NTRK gene fusions in patients with solid tumors.
Boland Discusses Melanoma Treatment Updates
Genevieve Boland, MD, PhD, discusses the latest updates to the melanoma treatment landscape.
Dosing Strategies for Lenvatinib in Advanced Clear Cell RCC
An oncologist explains his dosing strategies for lenvatinib in advanced clear cell RCC, with reference to the design of the KEYNOTE-426 trial.
Rationale for Lenvatinib plus Pembrolizumab Therapy in Frontline Setting in Advanced Clear Cell RCC
Dr Moshe Ornstein shares his take on the survival, efficacy, and toxicity data of the CLEAR trial in advanced clear cell RCC.
Looking Ahead in the Treatment of Breast Cancer
William J. Gradishar, MD, discusses the questions ongoing studies are looking to answer in the breast cancer space.
Discussing the ViPOR Regimen in Mantle Cell Lymphoma
Christopher J. Melani, MD, discusses the combination investigated in the ViPOR study of patients with relapsed/refractory or untreated mantle cell lymphoma.
Increasing Burden of Early-Onset Appendiceal Cancer
Andreana Holowatyj, PhD, MSCI, discusses the rationale for her research on the growing increase of early-onset appendiceal cancer in the United States.
Preventing Thrombosis in Patients with Polycythemia Vera
Srdan Verstovsek, MD, PhD, discusses some of the best practices to try and prevent thrombosis in patients with polycythemia vera.
Tivozanib Shows Efficacy and Safety in Heavily Pretreated ccRCC
Helen H. Moon, MD, discusses the results of the TIVO-3 trial of tivozanib for patients with recurrent clear cell renal cell carcinoma.
Improving Outcomes for Patients With NSCLC and RET Alterations
Nathan A. Pennell, MD, PhD, discusses the importance of developing new RET inhibitors for patients with non–small cell lung cancer.
First-Line Treatment for Advanced RCC: Lenvatinib + Pembrolizumab
Centering discussion around the combination of lenvatinib + pembrolizumab in advanced clear cell RCC, Hans Hammers, MD, considers the role of this combination regimen in the first-line treatment setting.
Overview of the Treatment Landscape in Advanced Clear Cell RCC
Expert hematologist/oncologist Brian Rini, MD, spearheads a comprehensive discussion on the broad treatment landscape for advanced clear cell renal cell carcinoma.
Behind the FDA Approvals of BCMA-Directed Therapies for Multiple Myeloma
Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.
When to Use Targeted Therapy for Iodine-Refractory Thyroid Cancer
Krzysztof J. Misiukiewicz, MD, discusses when targeted therapy may be used for patients with NTRK-positive thyroid cancer.
Examining the KAMILLA Trial of Trastuzumab Emtansine in Metastatic Breast Cancer
Rachel Wuerstein, MD, discusses the KAMILLA trial of trastuzumab emtansine in metastatic breast cancer for both a global and Asian cohort.
Looking at the Future of Larotrectinib in NTRK Fusion+ Lung Cancer
David S. Hong, MD, discusses what he sees for the future of the NTRK inhibitor larotrectinib.
Research Explores Molecular Subtyping in Prostate Cancer.
Adam Weiner, MD, discusses the results of his research on molecular subtyping in prostate cancer.
Treatment Options After Relapse in CLL
Wojciech Jurczak, MD, PhD, discusses the available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who relapsed on BCL2 inhibitors.
Frontline Therapy in Advanced Clear Cell RCC: The CLEAR Trial
Scott Tykodi, MD, PhD, reviews data from the CLEAR trial investigating 2 IO combination therapies for advanced renal cell carcinoma treatment.
Single-Agent TKI Therapy in Favorable Risk Advanced Clear Cell RCC
Drs Tannir, Tykodi, and Ornstein debate whether single-agent TKI therapies still have a place in advanced clear cell RCC treatment, especially for favorable-risk patients.
Canakinumab Fails to Improve DFS in Resected NSCLC
Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.
7-Year OS of Maintenance Olaparib in SOLO1 Study
Paul A. DiSilvestro discusses the 7-year follow-up results from the phase 3 SOLO1/GOG-3004 trial.
Data Shows How Ruxolitinib is the Cornerstone of Treatment in Myelofibrosis
Ruben Mesa, MD, discusses crucial data from the COMFORT studies that show ruxolitinib's benefit in patients with myelofibrosis.
CAR T-Cell Use Generates Hope in Solid Tumors
Steven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.
Recommendations for Diagnosing and Treating Rare Histiocytic Neoplasms
Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.
Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 Insertion
Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Selecting a Treatment Regimen for Favorable Risk Advanced Clear Cell RCC
Moshe Ornstein, MD, MA, explains the factors he considers when deciding on a combination treatment regimen for a patient with favorable-risk advanced clear cell RCC.
Case Presentation: A Patient with Favorable Risk Advanced Clear Cell RCC
An expert presents the case of a 68-year-old woman with favorable-risk advanced clear cell RCC for discussion.
Future Directions for Treating Stage 1B, Grade 3 Endometrial Cancer
David Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.
